... FDA leadership and policymakers to better understand, and expand, on "what works." Broad patient engagement for HIV/AIDS and oncology medicines, flexible regulatory pathways first developed in the heat of the AIDS crisis, and rapid advances in the ...
http://ift.tt/1lKMTjR
http://ift.tt/1lKMTjR
No comments:
Post a Comment